We conducted a retrospective analysis comprising a total of 8077 consecutive SSR imaging studies recorded in our institutional database from 2006 to 2021. The final analysis included 229 patients. In 211 of 229 SSR-PET/CT imaging studies (92.1%) meningioma was accurately identified by both SSR-PET/CT and confirmed by histopathology. In 7 cases (4.8%), SSR-PET/CT detected meningioma that was not confirmed by histopathology (false-positive). Furthermore, in 11 cases (3.1%), meningioma was neither detected by SSR-PET/CT nor confirmed by histopathology (true-negative). SSR-PET/CT demonstrated a sensitivity of 100% (95% CI: 98.3 - 100%) and a specificity of 61.1% (95% CI: 35.8 – 82.7%) in detecting meningiomas. The positive predictive value (PPV) was 96.8% (95% CI: 93.5 - 98.7%), and the negative predictive value (NPV) was 100% (95% CI: 71.5 – 100%). The overall diagnostic accuracy was 96.9%, and the kappa statistic, indicating agreement between SSR-PET/CT and histopathology, was 74.3% (95% CI: 56.2 – 92.4%). Overall, our study aligns with the only study we identified comparing SSR-PET/CT and MRI with histopathology, which involved significantly fewer patients (n = 21 vs. n = 229 in our study). The results by Rachinger et al. demonstrated that [⁶⁸Ga]Ga-DOTA-TATE uptake strongly correlates with SSR expression in comparison to histopathologic analysis, offering high diagnostic accuracy in distinguishing meningiomas from tumor-free tissue, even in cases of recurrence after various therapies.